NCT01861756

Brief Summary

A cluster randomized trial to assess the efficacy of the Diabetes Medication Choice decision aid among Greek patients with type 2 diabetes mellitus compared with usual care. The tool will serve as a facilitator for the Shared Decision Making process.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
204

participants targeted

Target at P75+ for not_applicable diabetes-mellitus-type-2

Timeline
Completed

Started May 2013

Geographic Reach
1 country

8 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2013

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

May 20, 2013

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 24, 2013

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2014

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2014

Completed
2.6 years until next milestone

Results Posted

Study results publicly available

March 13, 2017

Completed
Last Updated

March 13, 2017

Status Verified

January 1, 2017

Enrollment Period

9 months

First QC Date

May 20, 2013

Results QC Date

January 23, 2017

Last Update Submit

January 23, 2017

Conditions

Keywords

Shared Decision MakingDecision Aids

Outcome Measures

Primary Outcomes (1)

  • Overall Decisional Comfort (0-100, 100=no Conflict)

    Quality of the decision making process assessed by means of the Decisional Conflict Scale

    Day 1

Secondary Outcomes (4)

  • Degree of Patient Knowledge About Available Treatment Alternatives

    Day 1

  • Patient and Clinician Satisfaction With the Decision Making Process

    Day 1

  • Adherence With Antihyperglycemic Regimens as Reported by the Patient Himself/Herself or Assessed Utilizing the Pharmacy Records

    3 and 6 months after patient initial encounter

  • Glycemic Control (HbA1c)

    3 and 6 months after patient initial encounter

Study Arms (2)

Diabetes Medication Choice Decision Aid

EXPERIMENTAL
Other: Diabetes Medication Choice decision aid

Standard care

NO INTERVENTION

Interventions

The Diabetes Medication Choice decision aid cards provide information about medications commonly used to treat type 2 diabetes mellitus. The tool was originally developed and successfully evaluated by Mayo Clinic researchers.

Diabetes Medication Choice Decision Aid

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 diabetes mellitus for more than one year
  • Agree to be followed for at least 6 months
  • Willing to respond to survey questions immediately following the visit
  • HbA1c value between 7.5% and 10%
  • Need treatment intensification and there are more than one available treatment options

You may not qualify if:

  • Decide not to intensify treatment or to intensify treatment through lifestyle modification, which is a sine qua non for diabetes treatment
  • Is to transfer to another practice within the next 6 months
  • Significant cognitive (e.g. dementia) or sensory limitations (e.g. blind) or other reasons (e.g. fatigue, limited attention, sleep deprivation) for which, in the judgment of the study personnel, they could not reasonably provide written informed consent or be able to use the decision aid
  • Planning to enter a long-term care facility (e.g. nursing home) where medications will be administered by clinical personnel after hospital discharge
  • Enrolled in other studies that require prolonged participation and follow-up
  • Unable to speak Greek at a level necessary to complete the patient surveys and ensure involvement in decision making
  • Women known to be pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Tzanio General Hospital

Piraeus, Attica, Greece

Location

Private practice

Neapoli, Thessaloniki, Greece

Location

Nea Michaniona Health Center

Néa Michanióna, Thessaloniki, Greece

Location

Thermi S.A.

Thermi, Thessaloniki, Greece

Location

Alexandroupoli University Hospital

Alexandroupoli, Greece

Location

NIMTS Military Hospital

Athens, Greece

Location

Polikliniki General Hospital

Athens, Greece

Location

Private practice

Serres, Greece

Location

Related Publications (1)

  • Karagiannis T, Liakos A, Branda ME, Athanasiadou E, Mainou M, Boura P, Goulis DG, LeBlanc A, Montori VM, Tsapas A. Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial. BMJ Open. 2016 Nov 14;6(11):e012185. doi: 10.1136/bmjopen-2016-012185.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Results Point of Contact

Title
Dr. Apostolos Tsapas
Organization
Aristotle University Thessaloniki

Study Officials

  • Apostolos Tsapas, MD, MSc, PhD

    Aristotle University Of Thessaloniki

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Medicine

Study Record Dates

First Submitted

May 20, 2013

First Posted

May 24, 2013

Study Start

May 1, 2013

Primary Completion

February 1, 2014

Study Completion

August 1, 2014

Last Updated

March 13, 2017

Results First Posted

March 13, 2017

Record last verified: 2017-01

Locations